Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Recruiting

Antibody-Drug ConjugatesProspective Registry of ADC as First- and Second-line Treatment for Breast Cancer

Sponsor:

UCLA

Code:

NCT06774027

Conditions

HER2-negative Breast Cancer

HER2 Negative Breast Carcinoma

Metastatic Breast Cancer

HR+ HER2 Breast Cancer

Metastatic Triple Negative Breast Cancers

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Specimen collection

Non-Investigational Antibody-Drug Conjugates (ADC)

Medical Record Review

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-25. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2025-12-18.